MAY 30, 2013 12:00 PM PDT
Companion Diagnostics Co-Development: Are you ready?
Presented at the Clinical Diagnostics 2013 Virtual Event
15 50 961

Speakers:
  • Senior Staff Scientist, Medical Sciences R&D, Life Technologies
    Biography
      Janice Au-Young is a Senior Staff Scientist for Companion Diagnostics in the Medical Sciences R&D group at Life Technologies. She has a Ph.D. degree in Microbiology from the University of California, Davis and has performed post-doctoral research at NIH, MIT and UCSF. She has held senior positions working on target and biomarker identification in other leading genomic companies. Janice has been at Life Technologies since 2006 working on platforms in gene expression, genotyping and mutation detection. Currently, her focus is on molecular diagnostics and defining Companion Diagnostics applications whether it is TaqMan qPCR, Capillary Electrophoresis sequencing, or Ion Torrent Next Gen Sequencing.
       

    Abstract:
    Development of a companion diagnostic can be critical to the success of a drug. Pharmaceutical companies are committing more and more of their efforts to discover and deliver targeted therapies especially in oncology. As the number of such drugs increases, there will be more and more demand for diagnostics which will predict which patients will benefit from which drug. Our Companion Diagnostics Partner Program is designed to help pharmas and biotechs by providing a breadth of assays and platforms that can be leveraged for the development of new diagnostics. Our genetic platforms include next gen sequencing, Sanger sequencing and qPCR. At Life Technologies, we are uniquely positioned to provide pharmas with flexible, strategic and cost-effective means to develop and commercialize drugs with companion diagnostics.  

    Show Resources
    Loading Comments...